logo

Applied Therapeutics Inc. (APLT)



Trade APLT now with
  Date
  Headline
2/11/2021 7:41:38 PM Applied Therapeutics Prices Public Offering Of 3 Mln Shares At $23.00/shr
2/1/2021 7:16:52 AM Applied Therapeutics: FDA Lifts Hold And AT-007 ACTION-Galactosemia Kids Pediatric Clinical Study To Begin
9/24/2020 8:24:01 AM Applied Therapeutics: FDA Grants AT-007 Both Pediatric Rare Disease, Orphan Drug Designation For PMM2-CDG Treatment
8/11/2020 7:17:26 AM Applied Therapeutics Q2 Net Loss $28.1 Mln Or $1.27/Shr Vs Loss $8.4 Mln Or $0.60/Shr Last Year
7/17/2020 7:12:50 AM Applied Therapeutics To Present Data On AT-007 For Galactosemia At Galactosemia Foundation 2020 Virtual Conference
4/2/2020 7:11:23 AM Applied Therapeutics Announces IND And Investigator-Initiated Studies Of AT-001 In Critical COVID-19 Patients
3/13/2020 7:08:57 AM Applied Therapeutics 2019 Net Loss $45.5 Mln Or $3.55/Shr
1/23/2020 9:36:24 PM Applied Therapeutics Announces Pricing Of Its Public Offering Of 2.74 Mln Shares At $45.50/shr
1/8/2020 7:16:09 AM Applied Therapeutics Announces Positive Topline Results From Pivotal Phase 2 ACTION-Galactosemia Study Of AT-007
9/17/2019 7:01:41 AM Applied Therapeutics To Present Preclinical Data Highlighting AT-001
9/13/2019 7:08:27 AM Applied Therapeutics To Present Data Highlighting AT-001 For Diabetic Cardiomyopathy At HFSA Annual Scientific Meeting
9/4/2019 7:06:22 AM Applied Therapeutics Begins Phase 3 Registrational Trial Of AT-001 In Diabetic Cardiomyopathy (ARISE-HF)
8/12/2019 7:14:59 AM Applied Therapeutics Q2 Loss Per Share $0.60 Vs Loss $0.58 Last Year
6/24/2019 7:11:04 AM Applied Therapeutics Begins Phase 1/2 Study Of AT-007 In Galactosemia